|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Substance-Related Disorders | |||||
| Dyssocial Behavior | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Antisocial Personality Disorder | |||||
| Attention Deficit Disorder with Hyperactivity | |||||
| Disease | |||||
| Hyperkinesis | |||||
| 3 | More general conditions related to this trial | ||||
| Attention Deficit and Disruptive Behavior Disorders | |||||
| Disorders of Environmental Origin | |||||
| Dyskinesias | |||||
| Mental Disorders | |||||
| Mental Disorders Diagnosed in Childhood | |||||
| Nervous System Diseases | |||||
| Neurologic Manifestations | |||||
| Pathologic Processes | |||||
| Personality Disorders | |||||
| Signs and Symptoms | |||||
| 4 | Interventions listed in this trial | ||||
| Psychosocial treatment | |||||
| Anti-ADHD medication | |||||
| Assessment-and-Referral | |||||
| 5 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||